NASDAQ: GHRSGh Research PLC Stock
$21.11+0.66 (+3.23%)
Updated Oct 9, 2026
GHRS Price
$21.11
Fair Value Price
$4.03
Market Cap
$1.45B
52 Week Low
$12.04
52 Week High
$31.44
P/E
-21.11x
P/B
4.03x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$62.27M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.04
Operating Cash Flow
-$64M
Beta
1.02
Next Earnings
Nov 5, 2026
Ex-Dividend
N/A
Next Dividend
N/A
GHRS Overview
GH Research PLC is a clinical-stage biopharmaceutical company developing treatment for psychiatric and neurological disorders. The company focuses on therapies for treatment-resistant depression. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GHRS's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
GHRS
Ranked#221 of 463
Ranked#221 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.29 | A | |
| $7.81 | A | |
| $110.42 | A |
Be the first to know about important GHRS news, forecast changes, insider trades & much more!
GHRS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GHRS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GHRS ($21.11) is overvalued by 424.38% relative to our estimate of its Fair Value price of $4.03 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
GHRS ($21.11) is not significantly undervalued (424.38%) relative to our estimate of its Fair Value price of $4.03 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GHRS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GHRS due diligence checks available for Premium users.
Valuation
GHRS fair value
Fair Value of GHRS stock based on Discounted Cash Flow (DCF)
Price
$21.11
Fair Value
$4.03
Overvalued by
424.38%
GHRS ($21.11) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GHRS ($21.11) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GHRS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GHRS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-21.11x
Industry
10.59x
Market
49.9x
GHRS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.03x
Industry
5.07x
GHRS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GHRS's financial health
Profit margin
Revenue
$0.0
Net Income
-$15.1M
Profit Margin
0%
GHRS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$372.3M
Liabilities
$12.9M
Debt to equity
0.04
GHRS's short-term assets ($368.82M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GHRS's short-term assets ($368.82M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GHRS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
GHRS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$18.0M
Investing
$6.3M
Financing
$111.9M
GHRS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GHRS vs Biotech Stocks
Gh Research Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.